• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.

作者信息

Zhao Xiang-Yu, Xu Zheng-Li, Mo Xiao-Dong, Chen Yu-Hong, Lv Meng, Cheng Yi-Fei, Chen Huan, Chang Ying-Jun, Xu Lan-Ping, Wang Yu, Zhang Xiao-Hui, Liu Kai-Yan, Huang Xiao-Jun

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Peking-Tsinghua Center for Life Sciences, Beijing, China.

出版信息

Leukemia. 2022 Jan;36(1):267-270. doi: 10.1038/s41375-021-01351-w. Epub 2021 Jul 20.

DOI:10.1038/s41375-021-01351-w
PMID:34285344
Abstract
摘要

相似文献

1
Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.抢先输注供体来源的抗CD19嵌合抗原受体T细胞，对异基因造血干细胞移植后微小残留病阳性的B淋巴细胞白血病复发显示出有前景的抗白血病效果。
Leukemia. 2022 Jan;36(1):267-270. doi: 10.1038/s41375-021-01351-w. Epub 2021 Jul 20.
2
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.预防性输注供体来源的CD19嵌合抗原受体T细胞以预防异基因造血干细胞移植后高危B淋巴细胞白血病的复发。
Leukemia. 2024 Jun;38(6):1419-1422. doi: 10.1038/s41375-024-02251-5. Epub 2024 Apr 17.
3
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.供体来源的靶向CD19的T细胞输注可诱导复发的B细胞急性淋巴细胞白血病患者达到微小残留病阴性缓解，这些患者在单倍体造血干细胞移植后对供体淋巴细胞输注无反应。
Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.
4
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.供者来源的 CD19 CAR-T 细胞治疗移植后复发的 CD19 阳性 B-ALL。
Leukemia. 2021 Jun;35(6):1563-1570. doi: 10.1038/s41375-020-01056-6. Epub 2020 Oct 19.
5
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.异基因移植后复发的 B 细胞急性淋巴细胞白血病的 CD19 和 CD22 CAR-T 细胞治疗的联合应用。
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
6
CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.115例儿童和青年急性B淋巴细胞白血病患者的CD19特异性嵌合抗原受体T细胞治疗：长期随访
Cancer Res Treat. 2024 Jul;56(3):945-955. doi: 10.4143/crt.2023.1205. Epub 2024 Feb 13.
7
CD4CD25CD127 regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.CD4CD25CD127 调节性 T 细胞与 CD19 CAR-T 治疗复发/难治性 B 细胞急性淋巴细胞白血病的疗效相关。
Int Immunopharmacol. 2021 Jul;96:107742. doi: 10.1016/j.intimp.2021.107742. Epub 2021 May 11.
8
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.51 例难治/复发 B 急性淋巴细胞白血病患者接受低剂量 CD19 导向 CAR-T 细胞治疗的高效和安全性。
Leukemia. 2017 Dec;31(12):2587-2593. doi: 10.1038/leu.2017.145. Epub 2017 May 15.
9
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.人源化抗 CD19 CAR-T 细胞疗法和序贯异基因造血干细胞移植治疗难治/复发 B 淋巴细胞白血病的长期生存：CAR-T 细胞治疗的回顾性研究。
Front Immunol. 2021 Oct 29;12:755549. doi: 10.3389/fimmu.2021.755549. eCollection 2021.
10
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.双特异性 CAR-T 细胞靶向 CD19 和 CD22 治疗复发或难治性 B 细胞急性淋巴细胞白血病成人患者。
J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8.

引用本文的文献

1
Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience.T细胞充足的单倍体相合造血干细胞移植的优化：中国经验
Haematologica. 2025 Mar 1;110(3):562-575. doi: 10.3324/haematol.2024.286194.
2
[The present and future of haploidentical hematopoietic stem cell transplantation in China].[中国单倍型相合造血干细胞移植的现状与未来]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):625-628. doi: 10.3760/cma.j.cn121090-20240215-00061.
3
Profile of Dr. Xiao-Jun Huang.黄小军博士简介。

本文引用的文献

1
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.供者来源的 CD19 CAR-T 细胞治疗移植后复发的 CD19 阳性 B-ALL。
Leukemia. 2021 Jun;35(6):1563-1570. doi: 10.1038/s41375-020-01056-6. Epub 2020 Oct 19.
2
Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后复发/难治性急性淋巴细胞白血病的 CD19 嵌合抗原受体 T 细胞治疗的长期随访。
Cytotherapy. 2020 Dec;22(12):755-761. doi: 10.1016/j.jcyt.2020.08.002. Epub 2020 Aug 26.
3
Sci China Life Sci. 2024 Nov;67(11):2307-2308. doi: 10.1007/s11427-024-2686-y.
4
Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia.急性淋巴细胞白血病患者移植后可测量残留病呈阳性的危险因素。
Chin Med J (Engl). 2025 May 5;138(9):1084-1093. doi: 10.1097/CM9.0000000000003150. Epub 2024 Jul 9.
5
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.预防性输注供体来源的CD19嵌合抗原受体T细胞以预防异基因造血干细胞移植后高危B淋巴细胞白血病的复发。
Leukemia. 2024 Jun;38(6):1419-1422. doi: 10.1038/s41375-024-02251-5. Epub 2024 Apr 17.
6
"Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.现货异体 CAR 细胞治疗——被忽视的宿主移植物效应。
Curr Treat Options Oncol. 2023 May;24(5):409-441. doi: 10.1007/s11864-023-01061-8. Epub 2023 Apr 3.
7
Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.接受异基因造血干细胞移植的成年急性淋巴细胞白血病患者的免疫表型微小残留病监测
Front Oncol. 2023 Feb 22;13:1047554. doi: 10.3389/fonc.2023.1047554. eCollection 2023.
8
[Chinese expert consensus of allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia (2022)].《儿童急性淋巴细胞白血病异基因造血干细胞移植中国专家共识（2022年版）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):793-801. doi: 10.3760/cma.j.issn.0253-2727.2022.10.001.
9
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.联合策略优化嵌合抗原受体 T 细胞疗法在血液恶性肿瘤中的疗效。
Front Immunol. 2022 Aug 23;13:954235. doi: 10.3389/fimmu.2022.954235. eCollection 2022.
10
Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study.单倍体相合供体来源的记忆性嵌合抗原受体T细胞：首次人体经验及体外相关性研究
Blood Adv. 2022 Oct 11;6(19):5582-5588. doi: 10.1182/bloodadvances.2021006262.
Mechanisms of resistance to CAR T cell therapy.
CAR T 细胞治疗耐药的机制。
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6.
4
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.高通量测序检测可测量残留病可改善儿童 B-ALL 的风险分层。
Blood. 2018 Mar 22;131(12):1350-1359. doi: 10.1182/blood-2017-09-806521. Epub 2017 Dec 28.
5
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.供体来源的靶向CD19的T细胞输注可诱导复发的B细胞急性淋巴细胞白血病患者达到微小残留病阴性缓解，这些患者在单倍体造血干细胞移植后对供体淋巴细胞输注无反应。
Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.
6
Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后，针对急性白血病/骨髓增生异常综合征微小残留病，进行供体淋巴细胞输注并联合或不联合化疗的疗效比较。
Ann Hematol. 2017 May;96(5):829-838. doi: 10.1007/s00277-017-2960-7. Epub 2017 Mar 11.
7
Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.供体来源的嵌合抗原受体T细胞：无移植物抗宿主病的移植物抗恶性肿瘤效应，一项系统综述
Immunotherapy. 2017 Jan;9(2):123-130. doi: 10.2217/imt-2016-0127.
8
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.表达抗CD19嵌合抗原受体的同种异体T细胞可诱导异基因造血干细胞移植后进展的B细胞恶性肿瘤缓解，且不引起移植物抗宿主病。
J Clin Oncol. 2016 Apr 1;34(10):1112-21. doi: 10.1200/JCO.2015.64.5929. Epub 2016 Jan 25.
9
Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.异基因造血干细胞移植后，采用挽救性化疗联合粒细胞集落刺激因子预处理的供者白细胞输注并控制移植物抗宿主病，用于治疗急性白血病/骨髓增生异常综合征的微小残留病：预后因素及临床结局
Eur J Haematol. 2016 Mar;96(3):297-308. doi: 10.1111/ejh.12591. Epub 2015 Jun 25.
10
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.供者来源的 CD19 靶向 T 细胞可导致异基因造血干细胞移植后持续存在的恶性肿瘤消退。
Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20.